132 related articles for article (PubMed ID: 9079368)
1. Mutational effects on inclusion body formation in the periplasmic expression of the immunoglobulin VL domain REI.
Chan W; Helms LR; Brooks I; Lee G; Ngola S; McNulty D; Maleeff B; Hensley P; Wetzel R
Fold Des; 1996; 1(2):77-89. PubMed ID: 9079368
[TBL] [Abstract][Full Text] [Related]
2. Heat-induced native dimerization prevents amyloid formation by variable domain from immunoglobulin light-chain REI.
Nawata M; Tsutsumi H; Kobayashi Y; Unzai S; Mine S; Nakamura T; Uegaki K; Kamikubo H; Kataoka M; Hamada D
FEBS J; 2017 Sep; 284(18):3114-3127. PubMed ID: 28736891
[TBL] [Abstract][Full Text] [Related]
3. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain.
Kobayashi Y; Tsutsumi H; Abe T; Ikeda K; Tashiro Y; Unzai S; Kamikubo H; Kataoka M; Hiroaki H; Hamada D
Biochemistry; 2014 Aug; 53(31):5162-73. PubMed ID: 25062800
[TBL] [Abstract][Full Text] [Related]
4. Intrabody construction and expression. I. The critical role of VL domain stability.
Ohage E; Steipe B
J Mol Biol; 1999 Sep; 291(5):1119-28. PubMed ID: 10518947
[TBL] [Abstract][Full Text] [Related]
5. Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency.
Tan PH; Sandmaier BM; Stayton PS
Biophys J; 1998 Sep; 75(3):1473-82. PubMed ID: 9726949
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins.
Wall JS; Gupta V; Wilkerson M; Schell M; Loris R; Adams P; Solomon A; Stevens F; Dealwis C
J Mol Recognit; 2004; 17(4):323-31. PubMed ID: 15227639
[TBL] [Abstract][Full Text] [Related]
7. The Antibody Light-Chain Linker Is Important for Domain Stability and Amyloid Formation.
Nokwe CN; Hora M; Zacharias M; Yagi H; John C; Reif B; Goto Y; Buchner J
J Mol Biol; 2015 Nov; 427(22):3572-3586. PubMed ID: 26408269
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment.
Arndt KM; Müller KM; Plückthun A
Biochemistry; 1998 Sep; 37(37):12918-26. PubMed ID: 9737871
[TBL] [Abstract][Full Text] [Related]
9. A role for destabilizing amino acid replacements in light-chain amyloidosis.
Hurle MR; Helms LR; Li L; Chan W; Wetzel R
Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5446-50. PubMed ID: 8202506
[TBL] [Abstract][Full Text] [Related]
10. Folding and assembly of an antibody Fv fragment, a heterodimer stabilized by antigen.
Jäger M; Plückthun A
J Mol Biol; 1999 Feb; 285(5):2005-19. PubMed ID: 9925781
[TBL] [Abstract][Full Text] [Related]
11. Both the environment and somatic mutations govern the aggregation pathway of pathogenic immunoglobulin light chain.
Davis DP; Gallo G; Vogen SM; Dul JL; Sciarretta KL; Kumar A; Raffen R; Stevens FJ; Argon Y
J Mol Biol; 2001 Nov; 313(5):1021-34. PubMed ID: 11700059
[TBL] [Abstract][Full Text] [Related]
12. Biophysical properties of human antibody variable domains.
Ewert S; Huber T; Honegger A; Plückthun A
J Mol Biol; 2003 Jan; 325(3):531-53. PubMed ID: 12498801
[TBL] [Abstract][Full Text] [Related]
13. Intrabody construction and expression. II. A synthetic catalytic Fv fragment.
Ohage EC; Wirtz P; Barnikow J; Steipe B
J Mol Biol; 1999 Sep; 291(5):1129-34. PubMed ID: 10518948
[TBL] [Abstract][Full Text] [Related]
14. Folding of an antibody variable domain in two functional conformations in vitro: calorimetric and spectroscopic study of the anti-ferritin antibody VL domain.
Tsybovsky Y; Shubenok DV; Kravchuk ZI; Martsev SP
Protein Eng Des Sel; 2007 Oct; 20(10):481-90. PubMed ID: 17962224
[TBL] [Abstract][Full Text] [Related]
15. DNA binding by the VH domain of anti-Z-DNA antibody and its modulation by association of the VL domain.
Chen Y; Stollar BD
J Immunol; 1999 Apr; 162(8):4663-70. PubMed ID: 10202006
[TBL] [Abstract][Full Text] [Related]
16. Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies.
Kim SH; Schindler DG; Lindner AB; Tawfik DS; Eshhar Z
Mol Immunol; 1997; 34(12-13):891-906. PubMed ID: 9464525
[TBL] [Abstract][Full Text] [Related]
17. MAK33 antibody light chain amyloid fibrils are similar to oligomeric precursors.
Hora M; Sarkar R; Morris V; Xue K; Prade E; Harding E; Buchner J; Reif B
PLoS One; 2017; 12(7):e0181799. PubMed ID: 28746363
[TBL] [Abstract][Full Text] [Related]
18. The Role of Protein Thermodynamics and Primary Structure in Fibrillogenesis of Variable Domains from Immunoglobulin Light Chains.
Rennella E; Morgan GJ; Yan N; Kelly JW; Kay LE
J Am Chem Soc; 2019 Aug; 141(34):13562-13571. PubMed ID: 31364359
[TBL] [Abstract][Full Text] [Related]
19. Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils.
Marin-Argany M; Güell-Bosch J; Blancas-Mejía LM; Villegas S; Ramirez-Alvarado M
Protein Sci; 2015 Nov; 24(11):1829-40. PubMed ID: 26300552
[TBL] [Abstract][Full Text] [Related]
20. Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation.
Schormann N; Murrell JR; Liepnieks JJ; Benson MD
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9490-4. PubMed ID: 7568160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
